Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)

University Hospital, Caen100 enrolled

Overview

Background: In combination with hypomethylating drugs, venetoclax has recently changed the therapeutic management of patients with newly diagnosed acute myeloid leukemia (AML) for whom standard induction chemotherapy was not an option. Over and above the clinical benefits of this combination, the data show that more than half the patients did not show remission criteria, even after the first month's exposure to venetoclax. Hypothesis: To compare the mean residual venetoclax plasma concentrations obtained in patients who went into complete composite remission versus those who did not go into remission at the end of the first cycle of venetoclax + azacitidine treatment. Method: According to the French law, this is a multicenter, non-comparative, open-label, single-arm, interventional study with minimal risks and constraints. Selection, information and inclusion will concern adult patients (≥60 years) with a confirmed diagnosis of AML according to ELN 2022 guidelines. Included patients will be treated as standard care with a combination of venetoclax+azacitidine. This research protocol will not modify their usual care.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Adult Acute Myeloid Leukemia

Interventions

Blood sampling for venetoclax drug dosage (venous puncture)

Eligibility

Sex: ALLMin age: 60 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject must have a confirmed diagnosis of previously untreated AML (ELN 2022 criteria) within 28 days of the onset of symptoms. Only previous cytoreductive treatments (e.g. hydroxyurea) are authorized. 2. Subject must be ineligible for standard cytarabine and anthracycline induction therapy according to the following criteria: * Subject aged ≥ 75 years. * OR subject aged between 60 and 74 with at least one of the following comorbidities: * ECOG performance status: of 2 or 3. * cardiac history: heart failure requiring treatment, left ventricular ejection fraction ≤ 50%, chronic stable angina. * carbon monoxide diffusion capacity ≤ 65% or forced expiratory volume in one second ≤ 65%. * creatinine clearance between 30 and 45 mL/min/m². * liver damage (not related to AML) with total bilirubin between 1.5 and 3 × upper normal limit. * any other comorbidity deemed by the physician to be incompatible with standard induction chemotherapy. 3. Patients are eligible for the recommended standard treatment, i.e. a combination of venetoclax and a hypomethylating agent. 4. Subjects must voluntarily sign and date an informed consent form authorized by the relevant authorities. 5. The participation of the subject in another interventional study not interfering with the pathophysiological, pharmacological and clinical rationale of this protocol is possible. Exclusion Criteria: 1. blood leukocytes \>25 G/L. 2. Subject has already received anticancer treatment (drugs, surgery, radiotherapy) for AML, hematological malignancy or malignant cancer (within the last 2 years). 3. Subjects with AML with central nervous system involvement or promyelocytic type (AML-M3). 4. Subject to an uncontrolled intercurrent disease such as: * infection (viral, bacterial or fungal) requiring treatment; * symptomatic congestive heart failure; * unstable angina pectoris * cardiac arrhythmia * psychiatric illness or drug addiction that would limit compliance with study requirements (risk of treatment non-adherence or low venous capital). 5. Documented hypersensitivity to the drugs used to treat the subject. 6. Subject has been exposed to potent CYP450 inducers or inhibitors (including grapefruit, Seville oranges) within 7 days prior to treatment initiation.

Outcomes

Primary Outcomes

Comparison of mean plasma residual concentration of venetoclax

To compare the mean plasma residual concentration (ng/mL) of venetoclax (determined by LC-MS-MS) between patients who have entered composite complete remission (defined by the presence of remission criteria ≥ CRi, according to ELN 2022 guidelines) versus those who have not at the end of the first cycle of venetoclax+azacitidine treatment.

Time frame: 1 month

Secondary Outcomes

Study relationship between mean plasma residual concentration of venetoclax and remission occurrence

To estimate mean residual plasma concentrations (Cres, ng/mL) of venetoclax and azole antifungals during patients' usual care. Then study the relationship between mean venetoclax Cres and the achievement (or non-achievement) of remission over time (according to ELN 2022 guidelines) .

Time frame: 24 months

Study performance of mean venetoclax Cres

To evaluate the performance (ROC curve) of mean venetoclax Cres (ng/mL) as a predictive biomarker of event-free survival (EFS) at 6 and 12 months.

Time frame: 6 and 12 months

Study survival

To estimate event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS).

Time frame: 24 months

Study early deaths

To estimate the proportion of early deaths at 30 and 60 days post-inclusion.

Time frame: 24 months

Study the variability of plasma venetoclax and antifungal concentrations over time

To estimate the inter-individual (IIV) and intra-individual (IOV) variability of plasma venetoclax and antifungal concentrations over time.

Time frame: 24 months

Study the impact of parameters in uni- and multivariate analyses.

To estimate the impact of the following parameters to the diagnosis of remission or Cres (venetoclax): * patient characteristics: age \[years\], BMI (\[kg/m²\], sex\[male vs female\], ECOG \[1,2 or 3\], comorbidities reported in inclusion criteria, number of cytopenia grade\>2, according to CTCAE v5, white blood cell count \[G/L\], creatininemia \[µmol/L\], cytoreduction (yes or not). * disease: AML classification (ELN 2022 guidelines), blast counts (G/L), cytogenetic status (fail, normal or not) and report, genetic status and report, abnormal rearrangement of genetic material and report. * and (co-)treatments of interest: fluconazole, isavuconazole, itraconazole, posaconazole, voriconazole, cannabidiol, ciclosporine, clarithromycine, diltiazem, ritonavir, verapamil,milk thistle, licorice; bosentan, carbamazépine, efavirenz, enzalutamide, felbamate, phénytoïne, phénobarbital, rifampicine, St. John's wort, grapefruit, bitter orange, star fruit).

Time frame: 24 months

Study adverse events of interest

To compare mean venetoclax Cres between patients who have experienced one or more of the 5 AEs of interest versus those who have not over time.

Time frame: 24 months

Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts